Inosine 5'-monophosphate dehydrogenase activity as a biomarker in the field of transplantation

Clinica Chimica Acta

Volumn 413, Issue 17-18, 2012, Pages 1391-1397

  Glander, Petra ^a   Hambach, Pia ^a   Liefeldt, Lutz ^a   Budde, Klemens ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Biomarker; IMP dehydrogenase; Transplantation

Indexed keywords

BIOLOGICAL MARKER; INOSINATE DEHYDROGENASE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MECHANISM; DRUG MONITORING; DRUG RESPONSE; ENZYME ACTIVITY; ENZYME ASSAY; GRAFT RECIPIENT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; NONHUMAN; ORGAN TRANSPLANTATION; OUTCOME ASSESSMENT; PERIPHERAL BLOOD MONONUCLEAR CELL; PERSONALIZED MEDICINE; PHARMACODYNAMIC MONITORING; PHARMACOGENETICS; PRIORITY JOURNAL; PROTEIN FUNCTION; RADIOENZYMATIC ASSAY; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS;

BIOLOGICAL MARKERS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IMP DEHYDROGENASE; MYCOPHENOLIC ACID; ORGAN TRANSPLANTATION; TREATMENT OUTCOME;

EID: 84862768024     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2011.08.027     Document Type: Review

References (66)

1. Srinivas T.R., Kaplan B., Meier-Kriesche H.U. Mycophenolate mofetil in solid-organ transplantation. Expert Opin Pharmacother 2003, 4:2325-2345.
2. Sanford M., Keating G.M. Enteric-coated mycophenolate sodium: a review of its use in the prevention of renal transplant rejection. Drugs 2008, 68:2505-2533.
3. Danovitch G.M. Mycophenolate mofetil: a decade of clinical experience. Transplantation 2005, 80:S272-S274.
4. Knight S.R., Morris P.J. Does the evidence support the use of mycophenolate mofetil therapeutic drug monitoring in clinical practice? A systematic review. Transplantation 2008, 85:1675-1685.
5. van Gelder T. Mycophenolate blood level monitoring: recent progress. Am J Transplant 2009, 9:1495-1499.
6. Kuypers D.R.J., Le Meur Y., Cantarovich M., et al. Consensus report on therapeutic drug monitoring of mycophenolic acid in solid organ transplantation. Clin J Am Soc Nephrol 2010, 5:341-358.
7. Yatscoff R.W., Aspeslet L.J., Gallant H.L. Pharmacodynamic monitoring of immunosuppressive drugs. Clin Chem 1998, 44:428-432.
8. Weimert N.A., Derotte M., Alloway R.R., Woodle E.S., Vinks A.A. Monitoring of inosine monophosphate dehydrogenase activity as a biomarker for mycophenolic acid effect: potential clinical implications. Ther Drug Monit 2007, 29:141-149.
9. Jackson R.C., Weber G., Morris H.P. IMP dehydrogenase, an enzyme linked with proliferation and malignancy. Nature 1975, 256:331-333.
10. Saccoccia P.A., Miech R.P. Inosinic acid dehydrogenase in mammalian tissues. Mol Pharmacol 1969, 5:26-29.
11. Proffitt R.T., Pathak V.K., Villacorte D.G., Presant C.A. Sensitive radiochemical assay for inosine 5'-monophosphate dehydrogenase and determination of activity in murine tumor and tissue extracts. Cancer Res 1983, 43:1620-1623.
12. Brouwer C., Vermunt-de Koning D.G.M., Trueworthy R.C., et al. Monitoring of inosine monophosphate dehydrogenase activity in mononuclear cells of children with acute lymphoblastic leukemia: enzymological and clinical aspects. Pediatr Blood Cancer 2006, 46:434-438.
13. Hedstrom L. IMP dehydrogenase: structure, mechanism, and inhibition. Chem Rev 2009, 109:2903-2928.
14. He X., Smeets R.L., Koenen H.J., et al. Mycophenolic acid-mediated suppression of human CD4+ T cells: more than mere guanine nucleotide deprivation. Am J Transplant 2011, 11:439-449.
15. Sintchak M.D., Fleming M.A., Futer O., et al. Structure and mechanism of inosine monophopsphate dehydrogenase in complex with the immunosuppressant mycophenolic acid. Cell 1996, 85:921-930.
16. Scott J.W., Hawley S.A., Green K.A., et al. CBS domains form energy-sensing modules whose binding of adenosine ligands is disrupted by disease mutations. J Clin Invest 2004, 113:274-284.
17. Pimkin K., Pimkina J., Markham G.D. A regulatory role of the Bateman domain of IMP dehydrogenase in adenylate nucleotide biosynthesis. J Biol Chem 2009, 284:7960-7969.
18. Kowalski R., Post D., Schneider M.C., et al. Immune cell function testing: an adjunct to therapeutic drug monitoring in transplant patient management. Clin Transplant 2003, 17:77-88.
19. Devyatko E., Zuckermann A., Bohdjalian A., et al. Activation of the purine salvage pathway in mononuclear cells of cardiac recipients treated with mycophenolate mofetil. Transplantation 2006, 82:113-118.
20. Barten M.J., van Gelder T., Gummert J.F., et al. Pharmacodynamics of mycophenolate mofetil after heart transplantation: new mechanisms of action and correlations with histologic severity of graft rejection. Am J Transplant 2002, 2:719-732.
21. Kamar N., Glander P., Nolting J., et al. Pharmacodynamic evaluation of the first dose of mycophenolate mofetil before kidney transplantation. Clin J Am Soc Nephrol 2009, 4:936-942.
22. Langman L.J., LeGatt D.F., Halloran P.F., Yatscoff R.W. Pharmacodynamic assessment of mycophenolic acid-induced immunosuppression in renal transplant recipients. Transplantation 1996, 62:666-672.
23. Sanquer S., Breil M., Baron C., Dahmane D., Astier A., Lang P. Induction of inosine monophosphate dehydrogenase activity after long-term treatment with mycophenolate mofetil. Clin Pharmacol Ther 1999, 65:640-648.
24. Brunet M., Martorell J., Oppenheimer F., et al. Pharmacokinetics and pharmacodynamics of mycophenolic acid in stable renal transplant recipients treated with low doses of mycophenolate mofetil. Transpl Int 2000, 13:301S-305S.
25. Balzarini J., De Clercq E. Assay method for monitoring the inhibitory effects of antimetabolites on the activity of inosinate dehydrogenase in intact human CEM lymphocytes. Biochem J 1992, 287:785-790.
26. Sanquer S., Maison P., Tomkiewicz C., et al. Expression of inosine monophosphate dehydrogenase type I and type II after mycophenolate mofetil treatment: a 2-year follow-up in kidney transplantation. Clin Pharmacol Ther 2008, 83:328-335.
27. Montero C., Duley J.A., Fairbanks L.D., et al. Demonstration of induction of erythrocyte inosine monophosphate dehydrogenase activity in ribavirin-treated patients using a high performance liquid chromatography linked method. Clin Chim Acta 1995, 238:169-178.
28. Griesmacher A., Weigel G., Seebacher G., Müller M.M. IMP-dehydrogenase inhibition in human lymphocytes and lymphoblasts by mycophenolic acid and mycophenolic acid glucuronide. Clin Chem 1997, 43:2312-2317.
29. Armstrong V.W., Oellerich M. New developments in the immunosuppressive drug monitoring of cyclosporine, tacrolimus, and azathioprine. Clin Biochem 2001, 34:9-16.
30. Glander P., Braun K.P., Hambach P., et al. Non-radioactive determination of inosine 5'-monophosphate dehydro-genase (IMPDH) in peripheral mononuclear cells. Clin Biochem 2001, 34:543-549.
31. Daxecker H., Raab M., Muller M.M. Influence of mycophenolic acid on inosine 5'-monophosphate dehydrogenase activity in human peripheral blood mononuclear cells. Clin Chim Acta 2002, 318:71-77.
32. Albrecht W., Storck M., Pfetsch E., Martin W., Abendroth D. Development and application of a high-performance liquid chromatography-based assay for determination of the activity of inosine 5'-monophosphate dehydrogenase in whole blood and isolated mononuclear cells. Ther Drug Monit 2000, 22:283-294.
33. Vethe N.T., Bergan S. Determination of inosine monophosphate dehydrogenase activity in human CD4+ cells isolated from whole blood during mycophenolic acid therapy. Ther Drug Monit 2006, 28:608-613.
34. Glander P., Sombogaard F., Budde K., et al. Improved assay for the nonradioactive determination of inosine 5'-monophosphate dehydrogenase activity in peripheral blood mononuclear cells. Ther Drug Monit 2009, 31:351-359.
35. Glander P., Hambach P., Braun K.P., et al. Effect of mycophenolate mofetil on IMP dehydrogenase after the first dose and after long-term treatment in renal transplant recipients. Int J Clin Pharmacol Ther 2003, 41:470-476.
36. Vethe N.T., Mandala R., Line P.D., Midtvedt K., Hartmann A., Bergan S. Inosine monophosphate dehydrogenase activity in renal allograft recipients during mycophenolate treatment. Scand J Clin Lab Invest 2006, 66:31-44.
37. Sombogaard F., van Schaik R.H.N., Mathot R.A., et al. Interpatient variability in IMPDH activity in MMF-treated renal transplant patients is correlated with IMPDH type II 3757T>C polymorphism. Pharmacogenet Genomics 2009, 19:626-634.
38. Fukuda T., Goebel J., Thogersen H., et al. Inosine monophosphate dehydrogenase (IMPDH) activity as a pharmacodynamic biomarker of mycophenolic acid effects in pediatric kidney transplant recipients. J Clin Pharmacol 2011, 51:309-320.
39. Mino Y., Naito T., Otsuka A., Ozono S., Kagawa Y., Kawakami J. Inosine monophosphate dehydrogenase activity depends on plasma concentrations of mycophenolic acid and its glucuronides in kidney transplant recipients. Clin Chim Acta 2009, 409:56-61.
40. Goldsmith D., Carry E.A., Ebury S., Smolenski R.T., Jagodzinski P., Simmonds H.A. Mycophenolate moftil, an inhibitor of inosine monophosphate dehydrogenase, causes a paradoxical elevation of GTP in erythrocytes of renal transplant patients. Clin Sci 2004, 107:63-68.
41. Nimmersgern E., Fox T., Fleming M.A., Thomson J.A. Conformational changes and stabilization of inosine 5'-monphosphate dehydrogenase associated with ligand binding and inhibition of mycophenolic acid. J Biol Chem 1996, 270:19421-19427.
42. Jagodzinski P., Lizakowski S., Smolenski R.T., Smolenska E.M., Goldsmith D., Simmonds H.A., et al. Mycophenolate mofetil treatment following renal transplantation decreases GTP concentrations in mononuclear leucocytes. Clin Sci 2004, 107:69-74.
43. Vethe N.T., Bremer S., Rootwelt H., Bergan S. Pharmacodynamics of mycophenolic acid in CD4+ cells: a single-dose study of IMPDH and purine nucleotide responses in healthy individuals. Ther Drug Monit 2008, 30:647-655.
44. Glander P., Sommerer C., Arns W., et al. Pharmacokinetics and pharmacodynamics of intensified versus standard dosing of mycophenolate sodium in renal transplant patients. Clin J Am Soc Nephrol 2010, 5:503-511.
45. van Gelder T., Le Meur Y., Shaw L.M., et al. Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Ther Drug Monit 2006, 28:145-154.
46. Stracke S., Shipkova M., Mayer J., et al. Pharmacokinetics and pharmacodynamics of mycophenolate sodium (EC-MPS) co-administered with cyclosporine in the early-phase post-kidney transplantation. Clin Transplant Feb. 7 2011, [Epub ahead of print]. 10.1111/j.1399-0012.2011.01403.x.
47. Gensburger O., Picard N., Marquet P. Effect of mycophenolate acyl-glucuronide on human recombinant type 2 inosine monophosphate dehydrogenase. Clin Chem 2009, 55:986-993.
48. Langman L.J., Nakakura H., Thliveris J.A., LeGatt D.F., Yatscoff W. Pharmacodynamic monitoring of mycophenolic acid in rabbit heterotopic heart transplant model. Ther Drug Monit 1997, 19:146-152.
49. Glander P., Hambach P., Braun K.P., et al. Pre-transplant inosine monophosphate dehydrogenase activity is associated with clinical outcome after renal transplantation. Am J Transplant 2004, 4:2045-2051.
50. van Gelder T. Mycophenolate mofetil: how to further improve using an already successful drug?. Am Journal 2005, 5:199-200.
51. Chiarelli L.R., Molinaro M., Libetta C., et al. Inosine monophosphate dehydrogenase variability in renal transplant patients on long-term mycophenolate mofetil therapy. Br J Clin Pharmacol 2010, 69:38-50.
52. Raggi M.C., Siebert S.B., Steimer W., Schuster T., Stangl M.J., Abendroth D.K. Customized mycophenolate dosing based on measuring inosine-monophosphate dehydrogenase activity significantly improves patients' outcomes after renal transplantation. Transplantation 2010, 90:1536-1541.
53. Sagcal-Gironella A.C., Fukuda T., Wiers K., et al. Pharmacokinetics and pharmacodynamics of mycophenolic acid and their relation to response to therapy of childhood-onset systemic lupus erythematosus. Semin Arthritis Rheum 2011, 40:307-313.
54. Sombogaard F., Peeters A.M.A., Baan C.C., et al. Inosine monophosphate dehydrogenase messenger RNA expression is correlated to clinical outcomes in mycophenolate mofetil-treated kidney transplant patients, whereas inosine monophosphate dehydrogenase activity is not. Ther Drug Monit 2009, 31:549-556.
55. Budde K., Glander P., Bauer S., et al. Pharmacodynamic monitoring of mycophenolate mofetil. Clin Chem Lab Med 2000, 38:1213-1216.
56. Haglund S., Taipalensuu J., Peterson C., Almer S. IMPDH activity in thiopurine-treated patients with inflammatory bowel disease - relation to TPMT activity and metabolite concentrations. Br J Clin Pharmacol 2007, 65:69-77.
57. Dayton J.S., Lindsten T., Thompson C.B., Mitchell B.S. Effects of human T lymphocyte activation on inosine monophosphate dehydrogenase expression. J Immunol 1994, 152:984-991.
58. Jain J., Almquist S.J., Ford P.J., et al. Regulation of inosine monophosphate dehydrogenase type I and type II isoforms in human lymphocytes. Biochem Pharmacol 2004, 67:767-776.
59. Wu T.-Y., Peng Y., Pelleymounter L.L., et al. Pharmacogenetics of the mycophenolic acid targets inosine monophosphate dehydrogenases IMPDH1 and IMPDH2: gene sequence variation and functional genomics. Br J Pharmacol 2010, 161:1584-1598.
60. Wang J., Zeevi A., Webber S., et al. A novel variant L263F in human inosine 5'-monophosphate dehydrogenase 2 is associated with diminished enzyme activity. Pharmacogenet Genomics 2007, 17:283-290.
61. Winnicki W., Weigel G., Sunder-Plassmann G., et al. An inosine 5'-monophosphate dehydrogenase 2 single-nucleotide polymorphism impairs the effect of mycophenolic acid. Pharmacogenomics J 2010, 10:70-76.
62. Grinyo J., Vanrenterghem Y., Nashan B., et al. Association of four DNA polymorphismus with acute rejection after kidney transplantation. Transpl Int 2008, 21:879-891.
63. Gensburger O., van Schaik R.H.N., Picard N., et al. Polymorphisms in type I and II inosine monophosphate dehydrogenase genes and association with clinical outcome in patients on mycophenolate mofetil. Pharmacogenet Genomics 2010, 20:537-543.
64. Maiguma T., Yosida T., Otsubo K., et al. Evaluation of inosin-5'-monophosphate dehydrogenase activity during maintenance therapy with tacrolimus. J Clin Pharm Ther 2010, 35:79-85.
65. Sommerer C., Müller-Krebs S., Schair M., et al. Pharmacokinetic and pharmacodynamic analysis of enteric-coated mycophenolate sodium: limited sampling strategies and clinical outcome in renal transplant patients. Br J Clin Phamacol 2010, 69:346-357.
66. Glander P., Hambach P., Mai M., et al. Time and dose dependent increase of IMPDH activity after transplantation in erythrocytes, but not in mononuclear cells. Transplantation 2006, 82:998. [Poster-Abstract].